At 4 weeks, IL1β expression showed no significant differences between the treatment groups, while at 8 weeks, grafts of the CKD + Pio group showed a significantly decreased expression of IL1β in comparison to the control group. This evidence concerns the gene IL1B and chronic kidney disease.